ARTICLE | Clinical News

AdipoCell: Additional Phase I data

March 24, 2014 7:00 AM UTC

Additional data from the Mexican Phase I ANGEL trial in 5 CHF patients showed that AdipoCell injection led to an average improvement of 6MWT of 68 meters from baseline to 6 months. Additionally, 80% of patients showed an improvement in their exercise capacity from 3 to 6 months post-injection. Patients also showed a significant average absolute improvement in ejection fraction of 10% from 3 to 6 months (p=0.01). Full 6-month data will be presented at the Age Management Medicine Group meeting in Orlando in April. Bioheart reported 3-month data from the trial last September (see BioCentury, Oct. 14, 2013). ...